Diabetes Drug Of India’s Dr. Reddy’s Hits Danish Trial Firm Problems
This article was originally published in PharmAsia News
Executive Summary
A Danish company conducting a Phase III trial on a diabetes drug for India's Dr. Reddy's Laboratories has encountered financial problems, possibly delaying the drug's introduction. Rheoscience has the Indian drug maker's balaglitizone in trials as a treatment for Type 2 diabetes and the drug was considered ahead of Indian competitors with launching possible as early as 2011. If Rheoscience cannot finish the trials, its parent, Nordic Bioscience is considered likely to finish them. (Click here for more
You may also be interested in...
SkyePharma Stops Feasibility Study On Drug Delivery Systems With Dr Reddy’s
Mumbai - London-based specialized drug delivery technology company SkyePharma announced as part of its management statement Oct. 27 that the collaborative feasibility project with Dr Reddy's Labs has been stopped pending further assessment
Chinese Firms Up Their Game In Novel Flu Antiviral Development
Joincare Pharmaceutical and partner TaiGen Biotechnology tout preliminary Phase III results in uncomplicated acute influenza for TG-1000, a homegrown follower of Shionogi/Roche’s oral antiviral Xofluza. Novel antivirals for flu were hotly pursued by Chinese developers throughout 2023.
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.